AxoGen (NASDAQ:AXGN) Stock Crosses Above Two Hundred Day Moving Average – Time to Sell?

AxoGen, Inc. (NASDAQ:AXGN – Get Free Report)’s stock price passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $39.28 and traded as high as $49.97. AxoGen shares last traded at $49.25, with a volume of 9,288,508 shares changing hands.

Here are the key news stories impacting AxoGen this week:
• Third-quarter earnings and revenue beat expectations. AxoGen reported adjusted earnings of $0.21 per share, compared with consensus estimates ranging from $0.13 to $0.14, while revenue reached $75.83 million versus expectations of approximately $73.18 million. Earnings also improved from $0.12 per share a year earlier.
• Management raised its full-year revenue guidance. AxoGen now expects 2026 revenue growth of at least 29%, equivalent to revenue of at least $290 million. The higher outlook signals continued demand for its nerve-repair products and supports improved investor expectations.
• Investor positioning turned notably bullish. Trading data showed purchases of 9,886 call options, nearly 11 times typical daily call volume. The activity may have amplified the stock’s move by signaling expectations for further gains or encouraging options-related buying.
• Broader biotechnology strength provided additional support. AxoGen was among several biotech stocks advancing strongly during the session, potentially attracting sector-focused buying.
• Profitability remains a risk. Despite the adjusted earnings beat, AxoGen continues to report a negative net margin and negative return on equity. Investors may therefore focus on whether revenue growth can translate into sustained GAAP profitability.

Several equities analysts have issued reports on AXGN shares. Bank of America initiated coverage on AxoGen in a research report on Monday, October 12th. They issued a “buy” rating and a $52.00 price objective for the company. Truist Financial decreased their target price on AxoGen from $60.00 to $53.00 and set a “buy” rating on the stock in a report on Thursday, October 1st. Lake Street Capital restated a “buy” rating on shares of AxoGen in a research note on Monday, October 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price target on shares of AxoGen in a report on Wednesday. Finally, Morgan Stanley downgraded shares of AxoGen to a “hold” rating in a research report on Tuesday, September 29th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, AxoGen presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.

The firm has a market cap of $2.65 billion, a P/E ratio of -72.43 and a beta of 1.17. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average of $42.78 and a 200-day moving average of $39.28.

AxoGen (NASDAQ:AXGN – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The company had revenue of $75.83 million during the quarter, compared to the consensus estimate of $73.18 million. On average, equities research analysts anticipate that AxoGen, Inc. will post -0.44 earnings per share for the current year.

In other AxoGen news, EVP Marc Began sold 67,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $47.34, for a total value of $3,195,450.00. Following the sale, the executive vice president owned 50,135 shares in the company, valued at $2,373,390.90. This trade represents a 57.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph Tyndall sold 3,500 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the sale, the director owned 10,650 shares in the company, valued at $529,305. This represents a 24.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 98,503 shares of company stock valued at $4,656,947. 2.44% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in AxoGen by 46.0% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 30,150 shares of the medical equipment provider’s stock valued at $1,264,000 after purchasing an additional 9,500 shares during the last quarter. Sterling Capital Management LLC grew its holdings in shares of AxoGen by 858.9% in the third quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 1,589 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in shares of AxoGen by 16.9% in the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock worth $118,000 after purchasing an additional 409 shares during the last quarter. Artemis Investment Management LLP grew its holdings in shares of AxoGen by 27.5% in the third quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock worth $74,659,000 after purchasing an additional 384,200 shares during the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of AxoGen in the second quarter worth $272,000. 80.29% of the stock is owned by institutional investors.

AxoGen, Inc NASDAQ: AXGN is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.
• Five stocks we like better than AxoGen
• Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
• Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
• Why Tesla’s Upside Is About More Than a SpaceX Merger

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AxoGen Right Now?

Before you consider AxoGen, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and AxoGen wasn’t on the list.

While AxoGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here…Read more by MarketBeat